Back to Portfolio


High performance linker technology for targeted cancer therapy


Antibody-Drug-Conjugates (ADCs) consist of cytotoxic agents attached to tumor-specific antibodies through a Linker enabling the selective delivery of the toxic drugs to the tumor tissue. To date, ADCs have faced challenges in the manufacturing process, stability issues and poor bioavailability leading to toxicities, lack of efficacy and drug resistance.

Araris’ proprietary linker technology and conjugation method aims to address these major short-comings. Its approach has the potential to drastically simplify and accelerate ADC manufacturing, improve performance, and widen options for treatment modalities and also significantly improve safety and tolerability in patients.